) The Survey Research Core (SRC) of the University of Colorado Comprehensive Cancer Center (UCCC) was implemented in October 1998 as a developmental core. During its brief 14 month history, the SRC has already conducted approximately 4,000 interviews for UCCC members, with an additional 2,000 interviews committed to the SRC from recently funded projects. In this competitive renewal, the SRC is seeking long-term support to allow continuation and expansion of core services, which include designing and conducting high quality surveys that utilize computer-assisted telephone interviews, face-to-face interviews and mail questionnaires. This centralized expertise in survey research methodology can be applied to pilot studies and needs assessment surveys, more extensive epidemiologic and population-based surveys, and randomized trials that obtain process and outcome data from patients and other target groups using interviews and questionnaires. The SRC is a full service core resource providing specific expertise spanning the full spectrum of survey research methodology, from sample design and questionnaire development to survey management of large data collection efforts. Funds are requested to expand utilization of the SRC to accommodate approximately 6,000 interviews per year. A new core service proposed herein involves utilizing the resources and expertise of the SRC to deliver telephone-based interventions in cancer prevention and control research, combined with the production and dissemination of tailored print material as a follow-up to telephone-delivered interventions. This strategic combination of intervention modalities would be highly innovative as a core resource, and should provide important new opportunities to promote and facilitate multidisciplinary cancer prevention and control research at the UCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589991
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Kim, Seongsoon; Park, Donghyeon; Choi, Yonghwa et al. (2018) A Pilot Study of Biomedical Text Comprehension using an Attention-Based Deep Neural Reader: Design and Experimental Analysis. JMIR Med Inform 6:e2
Altieri, Lisa; Miller, Kimberly A; Huh, Jimi et al. (2018) Prevalence of sun protection behaviors in Hispanic youth residing in a high ultraviolet light environment. Pediatr Dermatol 35:e52-e54
Kwak, Jeff W; Laskowski, Jennifer; Li, Howard Y et al. (2018) Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. Cancer Res 78:143-156
Hoefert, Jaimee E; Bjerke, Glen A; Wang, Dongmei et al. (2018) The microRNA-200 family coordinately regulates cell adhesion and proliferation in hair morphogenesis. J Cell Biol 217:2185-2204
Riemondy, Kent A; Gillen, Austin E; White, Emily A et al. (2018) Dynamic temperature-sensitive A-to-I RNA editing in the brain of a heterothermic mammal during hibernation. RNA 24:1481-1495
Sclafani, Robert A; Hesselberth, Jay R (2018) O Cdc7 kinase where art thou? Curr Genet 64:677-680
Shearn, Colin T; Orlicky, David J; Petersen, Dennis R (2018) Dysregulation of antioxidant responses in patients diagnosed with concomitant Primary Sclerosing Cholangitis/Inflammatory Bowel Disease. Exp Mol Pathol 104:1-8
Kim, Jihye; Yoo, Minjae; Shin, Jimin et al. (2018) Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association Studies with Traditional Chinese Medicine. Int J Genomics 2018:7697356
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36

Showing the most recent 10 out of 1634 publications